Funding for this research was provided by:
Fundación Bunge y Born
Agencia Nacional de Promoción Científica y Tecnológica (PICT 2015-2921))
Universidad de Buenos Aires (UBACYT20020170100779BA), UBACYT 20020130100843BA)
Sir Halley Stewart Trust
Received: 16 June 2021
Accepted: 26 September 2021
First Online: 20 October 2021
: Bolivian samples: the study protocol for collection of samples was approved by the Ethical Review Board of Vall d’Hebron Hospital (Barcelona, Spain), and all procedures were carried out in accordance with ethical standards laid out in the Helsinki Declaration as revised in 2000. All patients provided written informed consent, and samples were anonymised. Argentine samples: the collection, serological surveillance and treatment protocol were approved and supervised by the Dr. Carlos Barclay “Comité de Ética en Investigación Clínica” (Ethics Committee in Clinical Research), Buenos Aires, Argentina (IRB No. 00001678; Protocol No. TW-01-004), and all clinical investigations were carried out in accordance with principles of the Declaration of Helsinki. All individuals (or parents/guardians) provided written informed consent to participate in the serological surveillance and treatment. When information on the study was given to indigenous populations, an indigenous healthcare worker or community member was provided as translator [CitationRef removed]. The London School of Hygiene and Tropical Medicine (UK) Ethics Committee approved further work and secondary analysis of these samples.
: Not applicable.
: P.M. and Q.G. are employees of Coris BioConcept with no shares in the company.